Incyte has been granted a patent for a compound that inhibits PI3K-?, useful in treating autoimmune diseases, cancer, cardiovascular diseases, and neurodegenerative diseases. The compound is specifically defined as 2-(3-(8-Amino-6-(trifluoromethyl)imidazo[1,2-a]pyrazin-3-yl)-4-methylphenyl)-3,3,3-trifluoro-2-hydroxypropanamide or its salt. GlobalData’s report on Incyte gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Incyte Corp - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Incyte, Peptide pharmacophores was a key innovation area identified from patents. Incyte's grant share as of February 2024 was 42%. Grant share is based on the ratio of number of grants to total number of patents.

Compound for treating autoimmune diseases, cancer, cardiovascular, and neurodegenerative diseases

Source: United States Patent and Trademark Office (USPTO). Credit: Incyte Corp

A recently granted patent (Publication Number: US11926630B2) discloses a compound identified as 2-(3-(8-Amino-6-(trifluoromethyl)imidazo[1,2-a]pyrazin-3-yl)-4-methylphenyl)-3,3,3-trifluoro-2-hydroxypropanamide, or its pharmaceutically acceptable salt. This compound is claimed for its potential pharmaceutical applications.

Furthermore, the patent also covers a pharmaceutical composition that includes the aforementioned compound or its pharmaceutically acceptable salt, along with one or more pharmaceutically acceptable carriers. This composition is designed for use in the development of pharmaceutical products. The patent provides protection for the compound and its pharmaceutical composition, highlighting their potential significance in the field of medicine.

To know more about GlobalData’s detailed insights on Incyte, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies